Moving beyond #ALK TKIs - a first-in-class ALK molecular glue degrader that could change the game in ALK+ #NSCLC #AACR26.

返回会议原文

返回会议

LUNGevity Foundation· @LUNGevity · X·2026-04-20 09:36· 2026-04-20评分60

TRI-611

解读

小分子药物化学 — CDK2、WEE1、SERD（非 KRAS）

TRI-611 · 会场出现的早期编号

正文 · 机器翻译

超越 #ALK TKI——一款首创的 ALK 分子胶降解剂，可能改变 ALK+ #NSCLC 的格局 #AACR26。
为何选择降解剂而非另一种 TKI？获得性耐药不可避免。TRI-611 的作用方式不同 -> 招募 CRBN，彻底降解 ALK 蛋白，

热度 23 · 11 赞 · 1 回复 · 11 转发

会议摘要

4618按代号 TRI-611 对上

TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC including central nervous system metastases

Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella

读摘要原文 →

5787按代号 TRI-611 对上

TRI-611, a development stage molecular glue degrader of ALK, promotes the degradation of TKI-resistant ALK fusion proteins and leads to regression of ALK TKI-refractory tumors

Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Lauren Highfield, Nobuyuki Kondo, Aaron N. Hata, Kenneth Ngo, Jisu Lee, Prafulla C. Gokhale, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella

读摘要原文 →

来源：LUNGevity Foundation · x.com